NORD
Nordicus Partners Corporation4.9500
+0.2000+4.21%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
91.90MP/E (TTM)
-Basic EPS (TTM)
-0.28Dividend Yield
0%Recent Filings
8-K
10-Q
Q2 FY2026 results
Nordicus Partners posted a $1.5M net loss for Q2 FY2026 ended September 30, 2025, widening from $0.5M a year earlier, driven by ramped-up R&D at $0.5M (up 32% y/y) and higher officer pay amid board expansion, while revenue stayed flat at zero as a pre-revenue biotech accelerator. Operating loss hit $1.2M, up from $0.5M y/y, with net diverging due to a $0.3M fair-value drop in its Mag Mile investment. Cash climbed to $0.2M on $2.4M from stock issuances, funding $2.2M in ops burn, yet liquidity strains persist without debt. Acquisitions of Orocidin (May 2024, 3.8M shares for 95% stake, $15.7M IPR&D) and Bio-Convert (Nov 2024, 12M shares for 100%, $26.7M IPR&D) bolster its oral health portfolio, but clinical trial delays pose risks.
8-K
Private share issuance closed
Nordicus Partners closed a private placement on September 18, 2025, issuing 1,057,500 restricted common shares to 54 accredited investors at $1.90 per share, raising about $2 million. The deal, conducted from July through September, relied on exemptions under Section 4(a)(2) and Regulation D, avoiding public registration. Shares carry transfer restrictions. This bolsters liquidity without diluting public shareholders.
10-Q
Q1 FY2026 results
Nordicus Partners posted a Q1 FY2026 net loss of $1.2M, up from $0.3M a year ago, driven by $0.4M in new research and development costs for its preclinical biotech units Orocidin and Bio-Convert, while professional fees jumped 977% y/y to $0.3M on acquisition work. Operating loss widened to $0.8M from $0.3M, with the net gap stemming from a $0.4M decline in Mag Mile investment value. Cash dipped to $8K from $20K q/q after $0.4M burn, offset by $0.4M stock issuance; no debt burdens the balance sheet. Foreign currency gains boosted comprehensive income to $4.0M. Acquisitions of Orocidin in May 2024 for 3.8M shares (recognizing $15.7M IPR&D and $7.1M goodwill) and Bio-Convert in November 2024 for 12M shares ($26.7M IPR&D, $18.4M goodwill) fuel the pipeline. Yet regulatory hurdles could stall clinical progress.
8-K
Subsidiary asset valuations disclosed
Nordicus Partners disclosed independent valuations of its subsidiaries' key assets—Orocidin's QR-01 and Bio-Convert's QR-02—prepared by Stanton Park Advisors as of June 30, 2025, to aid board evaluation of fair market value. These reports, furnished under Regulation FD on August 11, 2025, draw from management discussions on operations, financials, and industry positioning. Valuations rely on forward-looking projections. Actual outcomes may vary materially from estimates.
BLNC
BALANCE LABS INC
1.55+0.00
BYNO
byNordic Acquisition Corporatio
12.15+0.00
EKSO
Ekso Bionics Holdings, Inc.
4.70+0.05
GLCP
-
1.00+0.00
GLVT
Greenlit Ventures Inc.
1.51+0.00
HAIAF
Healthcare AI Acquisition Corp.
12.74+0.00
HURN
Huron Consulting Group Inc.
179.14+0.74
NSYS
Nortech Systems Incorporated
7.17+0.18
SSHT
SSHT S&T Group Ltd.
0.04-0.01
ZBAI
ATIF Holdings Limited
7.21-0.74